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Abstract
Background and aims: Smoking is a crucial environmental factor in inflammatory bowel disease 
[IBD]. However, knowledge on patient characteristics associated with smoking, time trends of 
smoking rates, gender differences and supportive measures to cease smoking provided by 
physicians is scarce. We aimed to address these questions in Swiss IBD patients.
Methods: Prospectively obtained data from patients participating in the Swiss IBD Cohort Study 
was analysed and compared with the general Swiss population [GSP] matched by age, sex and year.
Results: Among a total of 1770 IBD patients analysed [49.1% male], 29% are current smokers. More 
than twice as many patients with Crohn’s disease [CD] are active smokers compared with ulcerative 
colitis [UC] [UC, 39.6% vs CD 15.3%, p < 0.001]. In striking contrast to the GSP, significantly more 
women than men with CD smoke [42.8% vs 35.8%, p = 0.025], with also an overall significantly 
increased smoking rate compared with the GSP in women but not men. The vast majority of smoking 
IBD patients [90.5%] claim to never have received any support to achieve smoking cessation, 
significantly more in UC compared with CD. We identify a significantly negative association of 
smoking and primary sclerosing cholangitis, indicative of a protective effect. Psychological distress 
in CD is significantly higher in smokers compared with non-smokers, but does not differ in UC.
Conclusions: Despite well-established detrimental effects, smoking rates in CD are alarmingly high with 
persistent and stagnating elevations compared with the GSP, especially in female patients. Importantly, 
there appears to be an unacceptable underuse of supportive measures to achieve smoking cessation.
Keywords:  Smoking; gender differences; smoking cessation
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1. Introduction
Smoking has a crucial impact on the clinical course and response 
to treatment in inflammatory bowel disease [IBD].1,2,3,4,5,6 It can be 
considered the most extensively investigated and replicated environ-
mental factor in IBD.7,8
Tobacco smoking has a clearly detrimental impact on the course 
of CD and increases the likelihood of stricturing and fistulising phe-
notype.9 In contrast, in UC smoking has a protective effect, with 
a substantially elevated risk of developing UC in former smokers 
compared with patients who never smoked 1,6,10,11,12,13 and a milder 
course of the disease in former smokers who resume smoking.3,14 
Moreover, whereas active smoking is a risk factor for developing 
early-onset CD, in UC the same holds true for previous smokers.15,16 
However, the reasons underlying the divergent impact of smoking on 
CD vs UC largely remain obscure.17
Smoking also influences the response to medical and surgical 
treatment. Among the factors associated with failure of anti-tumour 
necrosis factor [TNF] treatment for instance, ongoing smoking is 
important in CD,18,19 and interestingly also in other systemic immune 
diseases such as rheumatoid arthritis.20 Moreover, in CD smoking 
is a risk factor of primary intestinal resection21 and recurrence of 
stricture formation after dilation,22 and has been identified to be the 
strongest risk factor for postoperative recurrence, roughly doubling 
the risk.23,24,25 On the other hand, smoking cessation appears to have 
a beneficial impact on the further course of disease in CD.1,12
The mechanisms through which smoking affects the [divergent] 
course of disease in IBD are complex and hitherto only incompletely 
understood. Presumably a multitude of factors play a role, such 
as direct effects of various components of tobacco smoke [includ-
ing nicotine, free radicals, and carbon monoxide] on several effec-
tor targets, above all the mucus layer, the immune system function 
[cytokines, macrophage function], the microvasculature, and poten-
tially also epigenetics.8,17 Moreover, evidence on a direct effect of 
smoking status on intestinal microbial composition is increas-
ing.26,27,28 Unfortunately and in contrast to what has previously been 
assumed, therapeutic effects of nicotine replacement in UC are lim-
ited, with a risk of side effects.29
Current European CD guidelines advocate encouraging smoking 
cessation,30 whereas no such statement can be found in the respective 
UC guidelines.31,32 In UC, given the well-established beneficial effects 
of continuous smoking13 or low-dose smoking resumption in ex-
smokers,33 many physicians might hesitate to advocate smoking ces-
sation in UC patients. Yet in CD patients, there are only scarce data 
on the magnitude of support provided by treating physicians to cease 
smoking. Furthermore, knowledge on time trends of smoking rates in 
IBD patients compared with the general population is very limited.
Using data of the Swiss IBD Cohort Study [SIBDCS], a large, 
prospective, nationwide cohort study in Switzerland, we aimed to 
analyse patient characteristics associated with smoking including 
potential differences in terms of gender and education, psychological 
distress, and quality of life [QoL], and timetrends of smoking rates, 
as well as support received to cease smoking.
2. Materials and Methods
2.1. Swiss IBD Cohort Study
The SIBDCS is a nationwide disease-oriented prospective cohort 
study, having included patients from all over Switzerland since 
2006.34 The cohort study has been approved by all local ethical com-
mittees and receives continuous support from the Swiss National 
Science Foundation. All patients are followed up once a year and 
additionally in case of unscheduled events, such as a flare or hospi-
talisation. An annual questionnaire is sent to the patients covering 
the clinical disease course and various additional aspects includ-
ing psychosocial distress and QoL. All patients provided written 
informed consent to participate in the study.
2.2. Data extraction, definitions
Details on the methodology of data extraction are described else-
where.34 Patients were defined as smokers or non-smokers based on 
self-declaration from patients’ questionnaires. We deliberately decided 
against using data from the physicians’ questionnaires to define smok-
ing status, as it appears plausible that some smoking patients might not 
disclose their smoking status as appropriately as anonymously. Data 
regarding support to cease smoking as well as other factors associated 
to smoking status, such as level of education or country of origin, were 
also extracted from the patients’ questionnaires. Information on dis-
ease location and primary sclerosing cholangitis [PSC] was extracted 
from the physicians’ questionnaires. Data on the prevalence of smok-
ing in the GSP was obtained from a recent official monitoring report 
on the consumption of tobacco in Switzerland from the Bundesamt 
für Gesundheit der Schweiz [Swiss Federal Office for Public Health].35 
In this continuous survey on tobacco consumption, comprising an 
integral component of the Addiction Monitoring in Switzerland com-
missioned by the Swiss Federal Office for Public Health, a random 
sample of 2750 persons are surveyed every 3 months with general 
questions on the consumption of alcohol, tobacco, and other sub-
stances [core sample; among them 250 persons by mobile phone, the 
rest by a fixed network telephone interview; yielding a core sample set 
of 11 000 persons annually], whereas subsequent in-depth questions 
are posed in two split samples [1:1, Split A with alternating topics, 
Split B with an unchanged additional core with detailed information 
on tobacco consumption].
2.3. Psychological and quality of life measures
To assess psychological distress related to symptoms of anxiety and 
depression, we used the Hospital Anxiety and Depression Scale 
[HADS], a validated psychometric instrument with a subscale for 
anxiety [HADS-A] and depression [HADS-D]. Each subscale com-
prises seven items which are scored on a four-point Likert scale 
[0 = not at all, 3 = mostly] covering the previous 7 days; total scores 
for the HADS-A and HADS-D range between 0 and 21, with higher 
scores indicating greater levels of distress from anxiety and depres-
sion, respectively.36,37 Total scores are clinically interpreted with the 
following cut-off points: 0–7: no anxiety/depression; 8–10: mild 
anxiety/depression; 11–14: moderate anxiety/depression; 15–21: 
severe anxiety/ depression. Although as a self-rating instrument the 
HADS does not allow for a formal diagnosis of a psychiatric disor-
der, a score ≥ 8, defining the threshold for clinically relevant symp-
toms, has been shown to identify a major depressive disorder with 
a sensitivity of 82% and a specificity of 74%.38 The HADS has been 
validated multiple times not only in psychiatric but also somatic 
patients, as well as in the general population.39
The Short Form 36 Health Survey [SF-36] represents a question-
naire with 36 items on eight different dimensions, namely physi-
cal functioning, physical role, bodily pain, general health, vitality, 
social functioning, emotional role, mental health, and general health, 
designed to survey health status in a medical outcome study.40 For each 
of the subscales possible, scores range from 0 to 100 with a higher 
score representing a better health status.40,41 The SF-36 has been used 
in numerous clinical trials, including a variety of studies on gastro-
intestinal diseases.42 Due to its high reliability and validity, the SF-36 
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is considered to represent a valuable tool to measure health-related 
QoL.42
2.4. Statistical analysis
For statistical analysis we used SPSS [version 21; IBM, Armonk, NY, 
USA], Prism [version 6, GraphPad Software, La Jolla, CA, USA], and 
STATA [version 13.1, StataCorp, College Station, TX, USA] with level 
of significance set at a p-value ≤ 0.05. For a comparison of smoking 
rates within the cohort between males and females and CD vs UC 
patients, chi-square-testing was used. Chi-square was also applied to 
test for differences in having received support to cease smoking, an 
association between smoking and PSC, and an association of smok-
ing status and disease location, as well as for the exploration of other 
factors associated with smoking. To compare smoking rates within 
the cohort to the GSP, CochranArmitage testing was used. Regarding 
the comparison of HADS and SF-36 scores between smokers and 
non-smokers, a Wilcoxon MannWhitney rank-sum test was applied.
3. Results
3.1. Smoking rates overall and per type of IBD 
and sex
We analysed data from a total of 1770 IBD patients [49.1% male, 
56.7% with CD], ie all patients included in the cohort at the time of 
data extraction October 2012, where smoking status was available 
[80.2% of all patients included in the cohort at that point in time]. 
Overall, 29% of all IBD patients in the SIBDCS are current smok-
ers, but smoking rates differed substantially between type of IBD 
and sex [Figure 1]. More than twice as many patients with CD are 
active smokers compared with UC [39.6% vs 15.3%, p < 0.001]. In 
striking contrast to the GSP, where smoking rates in men are consist-
ently higher compared with women throughout all age groups, sig-
nificantly more women than men with CD smoke [42.8% vs 35.8%, 
p = 0.025]. In contrast, in UC patients there is no significant differ-
ence in smoking rates between women and men [13.2% vs 17%].
3.2. Smoking rates according to age groups and in 
comparison with the GSP
Comparing IBD patients overall with the GSP, smoking rates are 
roughly identical, with 29% in SIBDCS patients and 27% in the GSP 
[age 14–65, year 2010]. In terms of specific age groups, slight differ-
ences in smoking rates in the SIBDCS between 15 and 54 years of 
age and lower rates in the age group 55–65 appear to parallel those 
of the GSP. Significantly more women with IBD in the age groups 
35–44 and 45–54  years smoke compared with their counterparts 
in the GSP [whereas there is a non-significant trend of lower smok-
ing rates in male IBD patients Figure  2A]. In CD, women smoke 
significantly more often than in the GSP throughout all age groups, 
whereas smoking rates in men are similar to the GSP [Figure 2B]. 
Indeed, the highest smoking rate observed at all [51.7%] is found in 
women with CD aged 45–54 years, which is virtually twice as high 
as in the age- and sex-matched GSP [26.6%, p < 0.001]. In contrast, 
the smoking rates in UC are lower than in the GSP, with significant 
differences throughout most age groups [Figure 2C].
Since receiving an IBD diagnosis [especially the diagnosis of CD] 
early in life might modify subsequent smoking behaviour, we tested 
smoking rates according to age at IBD diagnosis. Age of diagnosis is 
not significantly associated with smoking rates in either CD or UC [in 
female CD patients, there is a non-significant lower smoking rate among 
those having received their diagnosis before the age of 20 compared with 
their counterparts who received their diagnosis thereafter, with 38.8% 
vs 43.8%].
3.3. Time trends of smoking rates in recent years
In the GSP, smoking rates have decreased from 2001 to 2012. We 
observe decreasing smoking rates on a similar level in Swiss IBD 
patients [Figure  3A]. However, looking at CD and UC patients 
separately, persistently higher smoking rates above the GSP can be 
observed in CD patients in our cohort [Figure 3B]. Of note, there 
is indication for a potential de novo rise in female patients, both in 
those with UC and those with CD [Figure 3B, C].
3.4. Support to cease smoking
All patients smoking when receiving their IBD diagnosis were asked 
[at inclusion in the SIBDCS] whether they previously had received any 
support to achieve smoking cessation. Among all smoking IBD patients, 
the majority [90.5%] claim to never have received any support to cease 
smoking. This number is significantly higher in UC compared with CD 
patients [97.4% vs 88.1%, p < 0.001]. We do not observe any differ-
ences in claimed support according to sex, age-group, level of educa-
tion or country of origin. Among the 9.5% of patients having received 
support, 2.2% of the total received a specialised consultation [struc-
tured smoking cessation programme] and 4.3% were counselled by 
their treating general physician [other form of support: 3%, Figure 4].
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Figure 1. Smoking rates among inflammatory bowel disease [IBD] patients overall and according to type of IBD and sex. Significant differences are highlighted 
in purple with respective p-values indicated.
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3.5. Smoking and PSC
In total, there are 26 patients [1.5% of all SIBDCS patients analysed] 
with a concomitant diagnosis of PSC [0.4% of CD and 3% of UC 
patients, respectively], in line with the lower end of the reported preva-
lence in the literature.43 Due to the relatively small sample size of IBD-
PSC cases, any conclusions have to be drawn with caution. Of note, 
however, is that within our cohort only one single PSC patient [female, 
concomitant CD] was a smoker. All other PSC cases were non-smokers, 
revealing a significant negative association between smoking and the 
occurrence of PSC in IBD [p = 0.002]. This negative association was 
significant among patients with UC [p = 0.04] but not in CD. However, 
with only 4 cases of PSC with CD, our study is underpowered for test-
ing in CD. According to our data, the negative association of smoking 
and PSC might be of special relevance in male patients [Figure 5].
3.6. Smoking and disease location
Whereas smoking rates are significantly lower in UC compared with 
CD patients, there is a non-significant trend towards an increased 
fraction of extensive disease with pancolitis in smoking compared with 
non-smoking UC patients [47% vs 38.3%; p = 0.077, non-significant]. 
Among CD patients, a significantly lower abundance of isolated colonic 
disease [L2 according to the Montreal Classification] can be observed 
in smokers vs non-smokers [24% vs 33.7%, p = 0.001 Figure 6].
3.7. Patient characteristics associated with smoking
Next, we investigated specific patient characteristics for a potential 
association with smoking status. An overview of these correlates of 
smoking is provided in Table 1. Having children is significantly asso-
ciated with a lower probability of active smoking in female but not 
in male IBD patients. Of note, IBD patients born in Switzerland are 
significantly more often active smokers compared with patients born in 
foreign countries. A higher formation level [higher job training or uni-
versity] is associated with lower smoking rates in IBD overall and in CD 
but not in UC. Moreover, receiving an invalidity pension is the strongest 
risk factor for smoking of all patient characteristics tested. As might be 
expected, regular physical activity [defined as doing sports at least once 
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Figure 2. Smoking rates across age groups for: inflammatory bowel disease [IBD] overall [A]; Crohn’s disease [CD] [B]; and ulcerative colitis [UC] [C]. Significance 
is indicated by colour of the bars with higher rates in comparison with the general Swiss population [GSP] depicted in red [A, B] and lower rates in green [C].
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Figure 3. Smoking rates [y-axis] of male [blue] and female [red] inflammatory bowel disease [IBD] patients are depicted at the year of inclusion in the cohort in 
comparison with the general Swiss population [GSP] for: all IBD [A]; Crohn’s disease [CD] [B]; and ulcerative colitis [UC] [C] patients.
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a week] appears to be associated with lower smoking rates. Frequent 
consumption of alcohol appears to be associated with smoking. While 
we do not observe a significant increase of moderate consumption [ie 
between once per week and less than daily], significantly more smoking 
vs non-smoking patients with UC [13.1% vs 6.9%] and smoking vs 
non-smoking men with IBD overall [16.7% vs 10.1%] claim to con-
sume alcohol at least once per day, equalling a relative risk [RR] of 
being a smoker of 1.91 [p = 0.02] and 1.65 [p = 0.01], respectively.
3.8. Features of complicated course of disease 
associated with smoking
We do not observe a significant increase in the risk of the composite 
‘any complications’, corresponding to a relative risk of 1.03 (confidence 
interval [CI] 0.92–1.15), 1.01 [CI 0.84–1.14], and 0.82 [CI 0.63–1.08] 
for smoking vs non-smoking IBD overall, CD, and UC, respectively. 
The same holds true for its individual complications, such as anaemia, 
perforation and peritonitis, colorectal dysplasia or cancer, gallstones, 
nephrolithiasis, massive haemorrhage, deep vein thrombosis, or pul-
monary embolism. However, the relative risk of current or past fistula 
formation is increased in smoking vsnon-smoking IBD patients [RR 
1.64; CI 1.35–1.98, p < 0.001], and so is the relative risk of current 
or past abscess [RR 1.58; CI 1.23–2.02, p < 0.001]. Likewise, there is 
an increased risk of current or past stenosis [RR 1.74; CI 1.46–2.09, 
p < 0.001], hospitalisation [RR 1.19; CI 1.02–1.39, p = 0.034], as well 
as surgery [RR 1.36; CI 1.19–1.54, p  < 0.001] in smoking vs non-
smoking IBD patients. With regard to medical treatment, current anti-
TNF administration is significantly more prevalent in smoking IBD 
patients, with a relative risk of 1.57 [CI 1.30–1.90, p <0.001], which 
seems to be even more pronounced in women [RR 1.74; CI 1.36–2.23, 
p < 0.001] compared with men [RR 1.34; CI 1–2.10, p = 0.056, not 
significant]. Concerning current use of steroids, we do not observe sig-
nificant differences between smoking and non-smoking IBD patients.
3.9. Psychological aspects associated with smoking 
and quality of life
Symptoms of anxiety and depression are both significantly asso-
ciated with active smoking in both female and male CD patients 
[p = 0.001 and p = 0.004 for HADS-A and p = 0.001 and p < 0.001 
for HADS-D sub-score in males and women, respectively]. In contrast, 
no differences in the levels of anxiety and depressive symptoms are 
observed in smoking vs non-smoking UC patients in either of the sexes 
[Figure 7 A,B].
In terms of the SF36 sub-scores, there are significantly higher 
values [ie better mood and less disability] in non-smoking male 
and female CD patients relative to their smoking CD counterparts 
[p = 0.005 and p < 0.001 for mood; p = 0.023 and p = 0.023 for dis-
ability in male and female patients, respectively Table 2]. Again, no 
such differences are observed in UC.
4. Discussion
Smoking can be considered the environmental factor in IBD that 
has most extensively been investigated. However, various smoking-
related issues are still open to question. In this study, we describe dif-
ferences in smoking rates according to the type of IBD, gender, age, 
and time, and identify differences in the clinical course of smoking vs 
non-smoking IBD patients. In addition, we address the provision of 
support to cease smoking by physicians for their IBD patients. Our 
No Support Spec. Consultant Gen. Phys. Other
CD UC
IBD
all together
Figure 4. Pie charts depicting support received for smoking cessation. The 
pie chart on the top represents all inflammatory bowel disease [IBD] patients, 
whereas the lower charts indicate support provided for Crohn’s disease 
[CD] and ulcerative colitis [UC] patients separately. Spec, specialised; Gen, 
general.
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Figure 5. The risk of a concomitant diagnosis of primay sclerosing cholangitis [PSC] in inflammatory bowel disease [IBD] patients is shown in per mille (‰, i.e. 
parts per thousand) according to sex, smoking status [S, smoking; NS, non-smoking] and type of IBD. Of note, in the SIBDCS the calculated risk is extremely low 
[approaching zero] in smoking IBD patients with only one single PSC case among smoking patients (a female Crohn’s disease [CD] patient). In the inlet on the 
upper left, the fraction of all PSC cases according to type of IBD, smoking, status and sex is shown in the pie chart.
 by guest on M
arch 16, 2016
http://ecco-jcc.oxfordjournals.org/
D
ow
nloaded from
 
Smoking in Ibd: Data from The Sibdcs 825
data indicate an alarmingly high prevalence of smoking, especially in 
women with CD [42.8%]. In this subgroup of patients, we identified 
the highest smoking rates of all, by far exceeding the smoking rates 
in the GSP throughout all age groups. Thus, our data identify women 
with CD as an important subgroup of IBD patients, where efficient 
and goal-directed counselling and support of medical profession-
als involved in the care of IBD patients is of particular necessity in 
achieving smoking cessation.
The significant higher rates of active smokers with CD compared 
with UC appears to be in line with the situation in Europe over-
all, where this phenomenon can be observed in western and eastern 
parts of the continent equally.15 However, to the best of our knowl-
edge, this is the first study reporting on this unexpected and sig-
nificant gender difference in CD. A former French study focusing on 
‘ever smokers’ and the effect of smoking on the course of colitis in 
both UC and CD revealed comparable smoking rates in CD between 
genders, with a slight male preponderance.44
Even though our analysis of associations cannot deconstruct the 
chain of cause and effect, we identified an increased psychosocial 
burden in smoking CD patients, as indicated by significantly higher 
levels of distress from anxiety and depressive symptoms and lower 
QoL. Anxiety and depression might on the one hand explain smoking 
behaviour but on the other hand also point to therapeutic options. 
Thus, our findings call for a need of increased awareness among phy-
sicians involved in the care of IBD patients, including for instance a 
low threshold for depression screening and provision of psychologi-
cal support, especially in female CD patients. Clearly, such screenings 
need to result in better patient care to be cost effective, as has been 
discussed elsewhere.45 Other high-risk groups of patients with spe-
cific needs for efficient counselling identified by our study are patients 
with a lower education level and those receiving an invalidity pen-
sion. Presumably, this may not extensively differ from the situation in 
the GSP. However, in view of the well-established devastating effect 
of smoking on the disease course in CD, probably potentiating the 
deleterious psychosocial effect of CD in itself on the one hand and 
impaired fitness for employment on the other, specific efforts from 
treating gastroenterologists appear mandatory in the latter subgroup 
of patients in particular. Moreover, the significant association of 
smoking and frequent [ie at least once daily, thus presumably delete-
rious] alcohol use should be recognised, specifically enquired about 
and considered as a potential adverse co-factor when provision of 
support to cease smoking is evaluated by the treating physician.
Counselling towards smoking cessation is an effective and cost-
effective medical intervention, and even a brief health education 
combined with advice to stop smoking successfully increase the fraction 
of quitters, remaining abstinent for 1 year or beyond.46 Importantly, the 
vast majority of our patients did not recall any intervention by physi-
cians regarding smoking cessation. Nevertheless, it should be borne 
in mind that individual patients may judge differently as to what type 
of action by the treating physician should be defined as support. For 
instance, whereas one patient may acknowledge a one-time encour-
aging statement from his treating physician as ‘support’, another 
patient may only declare having received support if he or she received 
a structured form of counselling on the different methods available 
for smoking cessation or an offer for referral to a specialist consulta-
tion. Furthermore, declaration of lacking support indeed might serve 
as a strategy to avoid self-awareness of one’s own insufficient motiva-
tion, discipline, and purposefulness, by transferring responsibility away 
from oneself to the treating physician, at least in some patients. Even 
though not all interventions might be remembered by patients and 
there may be heterogeneity in acknowledging any previous attempt of 
the physician to promote smoking cessation by patients [either invol-
untary or voluntary], our data point to missed opportunities for our 
patients. However, the ideal approach for counselling IBD patients 
remains unknown and future intervention studies are needed to devise 
efficient strategies. Intuitively, an early diagnosis of IBD might have an 
impact on the subsequent uptake of smoking habits. However, in our 
analysis a diagnosis of Crohn’s disease as a teenager had no detectable 
protective effect on subsequent smoking behaviour. The absence of any 
significant protection may be considered indicative of a lack of effec-
tive counselling of young patients regarding the potentially devastating 
impact of smoking status on the course of their disease, thus reinforc-
ing our above-mentioned conclusion.
In this regard, it is noteworthy that the genetic basis of CD and 
UC seem similar and the majority of single nucleotide polymor-
phisms [SNPs] associated with IBD increase the risk of both CD and 
UC.47 Accordingly, the genetic background would mostly shape the 
general IBD risk and environmental factors would influence the type 
of IBD. Our data, in line with previous studies suggesting that smok-
ers tend to develop deep penetrating inflammation associated with 
CD and fistulas but are protected from the superficial inflammation 
of UC, reinforce the relevance of smoking as representing one of the 
strongest environmental factors having an impact on the specifica-
tion of IBD in patients at risk. Of note, smoking cessation is the only 
modification of an environmental risk factor with robust evidence 
for a beneficial effect on disease course in CD.29,48
Regarding disease location, the observed association of smoking 
state and lower occurrence of isolated colonic disease [L2] in CD is 
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Figure 6. Distribution of disease location for Crohn’s disease [CD] [left side] and ulcerative colitis [UC] [right side] according to smoking state in percent [y-axis]. 
A significantly lower percentage of isolated colonic disease [L2] can be observed in smokers [highlighted in red]. In UC there is a non-significant trend for an 
increased abundance of pancolitis in smoking patients [highlighted in blue].
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noteworthy. It might be speculated that smoking exerts its influence 
via a positive modulation of the mucus layer predominantly in the 
colon, covering and protecting the mucosa, and/or a direct effect 
on intestinal microbial composition. Regarding the well-established 
microbial alterations in both subtypes of IBD, smoking may play 
a role, as recently suggested in a study comparing mucosa-associ-
ated microbial composition between smoking and non-smoking 
CD patients,26 and in our previous pilot study of healthy smokers 
undergoing smoking cessation.27,28 The impact of smoking state 
on intestinal microbial composition might differentially affect the 
ileal and colonic mucosa-associated microbiota and hence vulner-
ability towards and inadequate immune response against microbial 
antigens.
Our study, in concordance with the increasing body of evidence 
from the literature,49,50,51,52 suggests that smoking is a protective fac-
tor for the development of PSC in both UC and CD patients. The 
negative association of smoking with concomitant PSC appears to 
strongest in UC [Figure 5]. However, since we did not detect a sin-
gle case of PSC in smoking UC patients, no hazard ratio regarding 
PSC in non-smokers vs smokers can be calculated. Similar to the 
aforementioned investigations on risk of PSC according to smoking 
status, our study cannot serve as a mechanistic investigation on the 
underlying mechanism for the apparent benefit of cigarette smoking 
in IBD-PSC, for which the pathophysiology has not been sufficiently 
clarified.51 Of note, this protective effect appears to be independ-
ent of the well-known impact of smoking in UC, as the beneficial 
effect of smoking has likewise been observed in non-IBD PSC.51 
Presumably, systemic effects of cigarette smoke may play a role, such 
as alterations in cellular53 and humoral54 immunity, intestinal27,28 and 
potentially also biliary microbial composition, adrenal axis, and/or 
colonic mucus production.55,56,57
There is growing evidence of an increased colorectal cancer 
[CRC] risk in smokers in the general population,58 but smoking pro-
tects from PSC [see above]. Thus one might speculate that smoking 
might even have a paradoxical protective effect on colorectal cancer 
in IBD, as PSC has consistently been shown to increase the over-
all risk of colorectal cancer in IBD with a roughly 5-fold relative 
risk.59 Testing for a negative association of smoking on CRC devel-
opment in our cohort is limited by the small number of CRC cases. 
Nevertheless, it appears noteworthy that 8 out of 10 CRC cases 
occurred in non-smokers and 6 UC patients developing CRC were 
non-smokers. In any case, the detrimental health effects of smoking 
are undisputed, and patients with both CD and UC were recently 
shown to have a significantly increased risk of smoking-associated 
extraintestinal cancers, with a standardised incidence ratio of 1.3,60 
further underscoring the importance of smoking cessation in IBD 
patients.
Our study has several limitations. The SIBDCS is not fully 
population-based in that IBD patients recruited in hospitals are 
somewhat overrepresented. In addition, our data regarding smok-
ing, psychological health, and socioeconomic status rely entirely 
on patient reporting and might be subject to some level of invol-
untary or voluntary recall bias. However, the latter may be even 
more of concern, if questions regarding smoking are directly posed 
and recorded by physicians or other healthcare professionals, 
which is why we decided to only use the patient questionnaires’ 
data on smoking. Obtaining information on such a sensitive topic 
as consumption of a noxious substance is evidently a cumber-
some process and prone to various potential sources of bias. Any 
information on the number of cigarettes smoked per day as well as 
duration of smoking could have been of interest for our analyses. 
Unfortunately, no quantitative information on smoking is recorded 
Table 1. Smoking risk according to patient characteristics.
Factor Patient group Relative risk of being a smoker Significance
Having children All IBD 0.95 n.s.
Male IBD 0.98 n.s.
Female IBD 0.92 0.020
Related person with IBD All IBD 1.00 n.s.
Country of birth [Switzerland vs other country] All IBD 1.20 0.05
All UC 1.22 n.s.
All CD 1.20 n.s.
Higher job training / university All IBD 0.85 0.028
All UC 1.19 n.s.
All CD 0.80 0.007
Invalidity pension All IBD 1.83 < 0.001
All UC 1.57 n.s.
All CD 1.54 < 0.001
Low physical activity [sport less than once a week] All IBD 1.43 < 0.001
All CD 1.42 < 0.001
All UC 1.08 n.s.
Consumption of alcohol, every day [at least once daily] All IBD 1.31 n.s.
IBD, men only 1.65 0.01
IBD, women only 0.89 n.s.
All UC 1.91 0.027
All CD 1.08 n.s.
Consumption of alcohol, rarely [less than once per week] or never All IBD 0.95 n.s
IBD, men only 0.81 0.022
IBD, women only 1.0 n.s.
All CD 0.99 n.s.
All UC 0.68 0.001
IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; n.s., non significant.
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in the SIBDCS. In addition, there might be some heterogeneity, 
between those patients with a longer follow-up since enrolment 
and those patients with a more recent inclusion in the SIBDCS. 
However, there is no evident reason to assume that this potential 
bias substantially differs between the subgroups of patients we 
addressed in our analyses. In the general population, the methodol-
ogy of data collection may be even more challenging and evidently 
methods applied here for the GSP, as extensively described else-
where,35 differ in some aspects from those used in a longitudinal 
cohort study, which is why any comparisons have to be interpreted 
with some caution. Also, longitudinal annual follow-up within a 
cohort study cannot precisely determine the link between cause 
and effect of smoking and associated factors. For a subset of 
patients, smoking might serve as a means of addressing psychiatric 
or abdominal symptoms. A  prospective specific study with more 
frequent [weekly or even daily] quantitative recording of smoking 
and the outcome variable of interest would be necessary for a more 
precise analysis. Furthermore, even though we were able to include 
1770 patients, the number of individuals in several subgroups is 
too small for robust conclusions regarding some analyses. Finally, 
since our study is purely observational, all our conclusions need to 
be tested in future interventional studies.
One strength of our study is the prospective data acquisition by 
the SIBDCS throughout the whole of Switzerland, including IBD 
patients receiving care by gastroenterologists in private practice, 
smaller hospitals, and also tertiary referral academic centres. Thus 
within the SIBDCS a wide spectrum of data is available including 
clinical symptoms, a detailed previous history, history of disease, 
treatment record, and socioeconomic and psychosocial factors. 
Moreover, complementary data are acquired from both physicians 
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Figure 7. Percentages of no, mild, moderate [mod.] and severe [sev.] degree of anxiety [A] and depressive symptoms [B] according to sex and subtype of 
inflammatory bowel disease [IBD] in percent [y-axes]. Significant differences are observed in Crohn’s disease [CD] only [p-values given], whereas there are no 
significant [n.s.] differences in ulcerative colitis [UC].
Table  2. SF-36 for mood and disability. Sub-scores with mean 
values [median values in brackets] are depicted with respective 
p-values between smoking and non-smoking patients.
SF-36 Smoker Non-Smoker p-value
Mood CD Male 35 [36] 37.1 [38] 0.005
Female 32.7 [36.5] 35.8 [38] <0.001
UC Male 37 [37] 36.6 [38] n.s.
Female 36.6 [36.5] 35.5 [36] n.s.
Disability CD Male 26.6 [29] 27.3 [29] 0.023
Female 25.8 [27] 26.7 [28] 0.023
UC Male 28 [29] 27.1 [29] n.s.
Female 27.3 [29] 27 [29] n.s.
UC, ulcerative colitis; CD, Crohn’s disease; n.s., non significant.
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and patients, allowing a broad, profound, and reliable investigation 
of factors associated with smoking in IBD.
In conclusion, we identify an alarmingly high smoking rate 
in CD, especially in women, persistently elevated throughout 
our observation period. Moreover, smoking is significantly 
inversely associated to concomitant PSC in Swiss IBD patients. 
In addition, impaired mood, disability, anxiety, and depres-
sion are revealed to be associated with smoking. The extremely 
low rate of patients claiming to have received support from 
their treating physician[s] appears both worrisome and unac-
ceptable, suggesting a need for improvement [considering the 
well-established deleterious effects of smoking on the course 
of disease in conjunction with the proven beneficial impact of 
smoking cessation in CD—but also in UC, where the exten-
sive all-over net benefit of smoking cessation outweighs poten-
tial downsides, such as worsening UC activity13 or subsequent 
modest weight gain]61 The necessary efforts appear anything 
but insurmountable, as already minimal interventions, such as 
3 min of physician’s counselling, are of proven efficacy in suc-
cessfully enabling smoking cessation.46
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